Earnings Call · Q3 FY2024·2024-11-12

Q3 24EPS +100.00%*·Rev n/aQ2 24EPS -71.43%·Rev n/aQ1 24EPS +57.14%·Rev n/aQ4 23EPS -100.00%*·Rev n/a⚠ consensus missing

Eton Pharmaceuticals, Inc. ETON

David Krempa — Chief Financial Officer

Sean Brynjelsen — Chief Executive Officer

James Gruber — Chief Commercial Officer

−5.6%1d on move date−5.3% vs SPY3d+7.7%5d+3.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ETON calls or request research access.

More ETON calls Browse calls Request research access